NDAORALSOLUTION1 Generic Approved
Approved
Sep 2015
Lifecycle
Peak
Competitive Pressure
23/100
Clinical Trials
10
Data completeness
6/8 — Strong
FERRIPROX (deferiprone) by Chiesi is iron chelating activity [moa]. Approved for iron chelator [epc]. First approved in 2015.
Drug data last refreshed 9h ago · AI intelligence enriched 12h ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
FERRIPROX (deferiprone) is an oral iron chelator indicated for the treatment of iron overload in patients with chronic transfusion-dependent anemias, particularly thalassemia major and sickle cell disease. It works by binding and removing excess iron from the body through urinary excretion. The oral solution formulation provides a patient-convenient alternative to parenteral chelation therapies.
Peak3.1 years to LOE
FERRIPROX is in peak revenue phase with $4M in spending but faces significant competitive pressure (competitive score: 23/100), indicating a mature market with limited growth opportunities and a lean commercial footprint.
Mechanism of Action
Iron Chelating Activity
Pharmacologic Class:
Iron Chelator
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (10)
Combination Therapy of Deferiprone and N-Acetylcysteine for Treating Negative Symptoms in Schizophrenia
Started Sep 2026
80 enrolled
Schizoaffecitve DisorderSchizophrenia and Schizoaffective DisorderSchizophrenia and Predominant Negative Symptoms
Safety and Acceptability of Deferiprone Delayed Release Tablets in Patients With Systemic Iron Overload
Started Mar 2019
30 enrolled
Iron Overload Due to Repeated Red Blood Cell Transfusions
Safety and Efficacy of Early Treatment With Deferiprone in Infants and Young Children
Started Nov 2018
64 enrolled
Beta Thalassemia Major AnemiaIron Overload
Study of Parkinson's Early Stage With Deferiprone
Started Oct 2016
140 enrolled
Parkinson's Disease
Long-term Safety and Efficacy of Ferriprox® in Iron Overloaded Patients With Sickle Cell Disease or Other Anemias
Started May 2015
134 enrolled
Iron OverloadSickle Cell DiseaseOther Anemias
Worked on FERRIPROX at Chiesi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.